euro adhoc: Intercell AG / Financial (Hepatitis C Infection) Figures

euro adhoc: Intercell AG / Financial Figures
VWDNews - Vienna (Austria), March 6, 2006 - Vaccine company Intercell AG (VSE: ICLL) today announced its preliminary 2005 full year results. Intercell?s aggregate annual revenues increased from EUR 4.6 million in 2004 to EUR 8.5 million in 2005, or by 84.9

Highlights of rising and falling U.S. stocks
Investors Business Daily - Advanta Corp. ( ADVNA ) raised its regular quarterly dividends to 21.25 cents from 11.34 cents on Class A common stock. The Spring House, Pa., banking company also raised the dividend on Class B common shares to 25.5 cents from 13.61 cents. The

Clinical Trial Results Show That Peregrine's First-In-Class Anti-Viral
Medical News Today - Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that it will present top line data demonstrating that its first-in

Novelos Therapeutics Closes $15 Million Private Placement
Genetic Engineering News - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, announced that today, it closed its previously announced private placement resulting in $15.06 million in